TB-500 FAQ: Frequently Asked Questions About Safety and Research | TB-500 Safe
These are the most common questions about TB-500 that appear in search and in forum discussions about the research literature. Each answer is drawn from the peer-reviewed record and cites the specific study it references. Where the literature has no answer, that is said directly.
What is TB-500?
TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of Thymosin Beta-4 (Tβ4), an endogenous 43-amino-acid actin-sequestering protein. It weighs 796.9 daltons and carries the central actin-binding domain responsible for Tβ4's wound-healing and cell-migration activity [1]. It is studied primarily in rodent and equine wound-healing, angiogenesis, and tissue-repair models. It is not approved for human use.
What does TB-500 do in the body?
TB-500 is proposed to bind free G-actin monomers, regulate cell migration, promote angiogenesis via VEGFR2/VEGF signaling, and suppress NF-κB-driven inflammation [1][15]. These effects have been observed in preclinical muscle, tendon, cardiac, and neural tissue models. No validated human mechanism data exists for the TB-500 fragment specifically.
What are the side effects of TB-500?
The most commonly reported side effect is mild injection site redness and discomfort. Transient fatigue, nausea, and dizziness have been reported anecdotally. No controlled human safety trial has characterized the side effect profile for injectable TB-500. The full-length Tβ4 protein IV Phase I study found no serious adverse events in 54 healthy volunteers [16], but that data applies to the parent protein, not this fragment.
What are the negative effects of TB-500?
Beyond injection-site reactions, documented concerns include: pro-angiogenic activity that may promote tumor vascularization in oncologically susceptible individuals [12][13]; immune modulation of unknown long-term duration; complete absence of human injectable safety trial data; and composition variability in research-grade preparations [17]. None of these risks is precisely quantified for humans.
Is TB-500 safe to take?
No human clinical trials have evaluated injectable TB-500 safety. Animal studies show a generally favorable short-term profile. The FDA classifies TB-500 as a Category 2 bulk drug substance of safety concern, prohibiting pharmaceutical compounding for humans. All injected human use exists outside a regulated clinical framework; safety for humans is undemonstrated [16][20].
Is TB-500 safe for long-term use?
Long-term human safety is undocumented. The longest preclinical data point is a 6-month dystrophic mouse study showing no overt toxicity [11]. No multi-year human cohort data exists. Absence of reported harms in uncontrolled settings is not equivalent to demonstrated safety in a controlled trial [20].
Does TB-500 cause cancer or promote tumor growth?
TB-500 promotes angiogenesis via VEGF upregulation — the same pathway used by tumors. In mouse melanoma models, Tβ4 overexpression produced 4.3x more lung metastases and 4.4x greater tumor vascularization [12]. In human colon cancer tissue, Tβ4 stabilizes HIF-1alpha → VEGF pathway components [13]. No human study confirms or rules out cancer promotion from exogenous TB-500; researchers flag this as an unresolved concern.
Can the TB-500 peptide cause allergies to flare up?
TB-500 modulates immune cell migration and macrophage polarization [15][22]. Allergic sensitization or exacerbation of existing immune conditions is theoretically possible. No controlled human studies have quantified this risk. The Phase I Tβ4 data showed low anti-drug antibody rates (0.9–1.8%) but covers IV administration of the full protein, not the fragment [16].
Can TB-500 cause autoimmune reactions or affect the immune system?
Tβ4 fragment influences T-cell differentiation, macrophage M1/M2 polarization, and NF-κB signaling [15][22]. Theoretical autoimmune risk exists given this bidirectional immune-modulatory activity. No human autoimmune events have been formally reported in the literature. The risk is uncharacterized, not confirmed absent.
Does TB-500 affect the heart?
In rat coronary artery occlusion models, Tβ4 at 5.37 mg/kg IP reduced infarct size by 43% at 28 days [6]. In mouse coronary artery ligation models, Tβ4 promoted cardiomyocyte survival and upregulated Akt/ILK survival signaling [5]. These are rodent models; whether these effects translate to humans is unknown.
Does TB-500 increase hair growth?
Tβ4 promotes hair growth in rat and mouse models via activation, migration, and differentiation of hair follicle stem cells, including in transgenic Tβ4-overexpressing mice [4]. TB-500 shares the actin-binding properties underlying this effect. Human evidence specifically for hair growth is sparse.
What is the difference between TB-500 and BPC-157?
BPC-157 is a 15-amino-acid gastric-peptide fragment studied primarily in gut and tendon models via localized injection, with proposed NO-synthase mechanisms. TB-500 is a 7-amino-acid Tβ4 fragment with systemic angiogenic and cell-migration effects via G-actin sequestration and VEGF signaling. Different mechanisms, different tissue systems, different evidence bases. No peer-reviewed head-to-head study exists.
What are the potential risks and benefits of using TB-500 for injury recovery?
Preclinical data suggest accelerated tendon, ligament, muscle, and tissue repair in animal models [3][9][10]. Risks include: unknown long-term safety profile, WADA prohibition in competitive sport [18], absence of human clinical trials, pro-angiogenic activity raising cancer-risk concerns [12], and composition variability in unregulated supply chains [17].
How long does TB-500 take to work for injury healing?
Rodent wound-healing studies measure effects at 4–7 days; ligament repair studies at 4 weeks [3][9]. Equine musculoskeletal protocols reference 4–6 week administration windows. TB-500 metabolites are detectable in rat plasma from 0 to 72 hours after a single injection [19]. No human time-course data exists.
What is the half-life of TB-500 and how often should it be dosed?
No validated human half-life exists for injectable TB-500 fragment. Rat metabolite data shows the primary metabolite Ac-LK peaks at 0–6 hours; Ac-LKK is detectable up to 72 hours [19]. Full-length Tβ4 IV in humans has a half-life of 0.5–2.08 hours [16] — not directly applicable to the fragment. Dosing frequency from this data cannot be determined.
How much TB-500 should be taken per week during a loading phase?
This is a question about human dosing that published science cannot answer. Equine veterinary literature references 2–5 mg administered subcutaneously or intramuscularly 1–2 times per week during a 4–6 week period [18]. These are equine protocols, not validated human doses. No human clinical trial has established a loading protocol for TB-500.
How does subcutaneous vs intramuscular injection of TB-500 compare?
Most preclinical animal studies used intraperitoneal injection — not a clinically relevant route. Subcutaneous and intramuscular routes are referenced in equine contexts without head-to-head comparison [18]. No human pharmacokinetic data comparing routes exists for TB-500. The Phase I Tβ4 human study used intravenous administration [16].
Is TB-500 legal to use in research?
In the US, TB-500 is classified as a Category 2 bulk drug substance by the FDA (safety concerns; not permitted for pharmaceutical compounding for human use). It is commercially available as a research chemical outside that classification. Legal status for research use varies by jurisdiction; it is not approved for human use in the US, EU, or Australia. Separate rules govern veterinary contexts.
Is TB-500 banned by WADA and in competitive sports?
Yes. TB-500 and Thymosin Beta-4 are prohibited by WADA under the Prohibited List category for peptide hormones, growth factors, and related substances — banned both in- and out-of-competition [18]. A Canadian athlete received a 4-year ineligibility period in connection with a non-analytical positive for combined use with another peptide. The US Department of Defense has adopted aligned prohibitions.
Are there any human clinical trials on TB-500?
As of 2026, no completed Phase I/II human clinical trial on TB-500 (Ac-LKKTETQ) has been published. NCT07487363 is registered on ClinicalTrials.gov but its completion status was unconfirmed at time of research. All published human safety data covers the full Tβ4 protein (IV Phase I trial [16]; topical ophthalmic Phase II trial [23]) — the parent protein, not the heptapeptide fragment.
Can TB-500 help with tendon injuries and ligament repair?
In rodent models, local Tβ4 delivery (1 µg in fibrin sealant) produced superior biomechanical properties and collagen organization in surgically transected rat MCL at 4 weeks [9]. Multiple equine studies supported musculoskeletal use in horses. Human tendon trial data is entirely absent.
What is the difference between TB-500 and full-length Thymosin Beta-4?
Thymosin Beta-4 (Tβ4) is a 43-amino-acid endogenous protein. TB-500 is a synthetic 7-amino-acid fragment (positions 17–23) corresponding to the active actin-binding domain [1]. Most mechanistic and human safety literature covers the full protein; TB-500-specific studies are primarily doping-control and metabolite detection work [18][19]. Effects attributed to TB-500 are often extrapolated from Tβ4 research.
Does TB-500 promote angiogenesis and is that a safety concern?
Yes on both counts. TB-500 promotes new blood vessel formation via VEGF/HIF-1alpha upregulation [13] — the proposed mechanism of tissue repair benefit and the same pathway exploited by tumors. Mouse melanoma overexpression studies showed 4.3x more lung metastases and 4.4x greater tumor vascularization [12]. Researchers flag this as an unresolved safety concern. No human study resolves it.
Is there a risk of injection site reactions with TB-500?
Mild redness, swelling, and discomfort at the injection site are the most consistently reported effects. Severity appears low in documented reports; systemic reactions are uncommon. No controlled study has systematically characterized injection site reaction incidence for TB-500 in any species.
Is the product purity of research-grade TB-500 reliable?
Not reliably. A 2023 analytical study found that commercially available TB500/TB1000 products are 'not systematically consistent with their descriptions' [17]. Contamination risks — endotoxins, incorrect sequences, undisclosed excipients — are independent of the compound's pharmacology and represent a distinct safety hazard in the unregulated supply chain.
How does TB-500 compare to other peptides for recovery and healing?
TB-500's systemic mechanism (angiogenesis, cell migration, actin regulation) is distinct from BPC-157 (localized cytoprotection via NO), GHK-Cu (collagen synthesis via copper), and growth-hormone-releasing peptides (pituitary axis). Each has a different tissue specificity and evidence base. No head-to-head clinical outcomes data comparing these compounds exists.
Does TB-500 have neuroprotective effects on the brain?
In rat TBI models, Tβ4 at 30 mg/kg IP (initiated 6 hours post-injury) improved sensorimotor recovery, reduced cortical lesion volume, and enhanced hippocampal neurogenesis [7]. In a rat embolic stroke model, the optimal dose for day-56 neurological recovery was calculated at 3.75 mg/kg [8]. Human neurological data for TB-500 is absent.
Does TB-500 work for muscle tears and recovery from exercise?
In mouse myoblast assays, Tβ4 accelerated wound closure and recruited satellite cells to injury sites [10]. In dystrophic mice, 6 months of 150 µg twice weekly increased regenerating muscle fibers without improving grip strength [11]. Exercise-induced micro-tear recovery has not been studied in controlled human trials.
How long should a TB-500 research cycle last?
Preclinical studies typically use 4–8 week administration windows aligned to tissue repair endpoints [3][9][11]. The longest documented animal protocol is 6 months (dystrophic mouse model) [11]. No data on repeat-cycle safety exists in any species. Cycle length cannot be determined from the current literature for humans.
Can TB-500 be taken daily?
Daily dosing protocols for TB-500 are not well-represented in peer-reviewed preclinical literature — most studies used weekly or twice-weekly administration [11][22]. One NAFLD model used 12 mg/kg/day for 4 weeks [22] in mice. Daily human dosing is uncharacterized in any published study.
TB-500 Legal and Regulatory Status for Research Use
In the US, TB-500 (Ac-LKKTETQ) is classified as a Category 2 bulk drug substance by FDA (prohibits pharmaceutical compounding for humans). It is commercially available as a research chemical outside that pharmaceutical pathway. WADA prohibits it in competitive sport [18]. Legal status for research use varies by country. It has no IND-approved human clinical trial pathway published as of 2026.
TB-500 and WADA: Banned Status in Sport
TB-500 and Thymosin Beta-4 are prohibited by WADA under growth factors and growth factor modulators — banned in- and out-of-competition as a Non-Specified Substance [18]. A Canadian athlete received a 4-year ineligibility period for a non-analytical positive involving TB-500. US Department of Defense testing has adopted WADA-aligned prohibitions. Competitive athletes — in any sanctioned sport — should treat TB-500 as a prohibited substance.